Infectious Disease Book

http://www.fpnotebook.com/

Influenza Vaccine

Advertisement

  1. See Also
    1. Influenza
  2. Vaccine Production
    1. Virus strains chosen based on:
      1. Virulence
      2. Lack of immunity in community
      3. Technical limitations on virus culture
    2. Virus grown in 90 million hens eggs over 1 year
    3. Vaccine developed and potency tested over 6-7 months
      1. Inject sheep and testing antigenicity
      2. Measure effective hemagglutinin concentration
      3. Develop reference strains
  3. Vaccine Efficacy
    1. Prevents illness in 70% healthy people age <65 years
    2. Prevents 30-70% Pneumonia hospitalizations in elderly
  4. Indications for vaccine
    1. Age 65 years and older
    2. Nursing Home and Chronic care residents
    3. Chronic cardiopulmonary disease (e.g. Asthma): all ages
    4. Chronic disease requiring frequent hospitalization
    5. Long term Aspirin use under age 18 years
      1. Prevents Reye's Syndrome
    6. Vectors
      1. Health care workers
      2. Nursing home personnel
      3. Family members of high risk patients
    7. Essential service providers
    8. Students in Institutional settings
    9. Second or third trimester of pregnancy
    10. Human Immunodeficiency Virus
    11. Travel to tropics any time of year
    12. Travel to Southern Hemisphere April to September
    13. Pregnancy (second and third trimester)
    14. Breast Feeding
  5. Contraindications to Vaccination:
    1. Anaphylaxis to eggs or other vaccine components
    2. Reaction to thimerosal (in contact lens solution)
    3. Adults with acute febrile illness
    4. History of Guillain Barre Syndrome
  6. Protocol
    1. Site
      1. Adults and older children: Deltoid
      2. Infants and young children: Anterolateral thigh
    2. Timing
      1. Clinic Visits starting in September
      2. Nursing Homes in October-November (not too early!)
    3. Dosing Frequency
      1. Children (Age <9 years)
        1. Dosing: 2 doses, 1 month apart before December
      2. Adults and children over age 9 years
        1. Dosing: 1 dose per year before December
    4. Dose
      1. Age under 36 months: 0.25 ml
      2. Age 3 years or older: 0.50 ml
  7. Safety
    1. Influenza vaccine is safe in infants and children
      1. France (2004) Arch Pediatr Adolesc Med 158:1031
  8. References
    1. (1999) Preparing for the Next Pandemic telecast, CDC
    2. (1997) Am Fam Physician 56(1):279

Influenza virus vaccine (C0021403)

Definition (CSP)orthomyxovirus vaccine; the composition of the vaccine is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains; the vaccine is usually bivalent or trivalent, containing one or two influenza virus A strains and one influenza virus B strain.
Definition (MSH)Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed or attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.
Definition (HL7V3.0)influenza virus vaccine, NOS
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121) , Immunologic Factor (T129)
Englishflu vaccine, Flu Vaccines, Influenza Vaccine, Influenza Vaccines, Influenza virus vaccine, Influenza Virus Vaccines, Influenzavirus Vaccines
Spanishvacuna antigripal, vacuna contra el virus de la influenza, vacuna contra el virus Influenza, vacuna contra la gripe
CreditsDerived from the NIH UMLS (Unified Medical Language System)



Navigation Tree